20 YEARS OF 131IODINE-METAIODOBENZYLGUANIDINE (131I-MIBG) THERAPY UPFRONT: A RETROSPECTIVE ANALYSIS OF ACUTE TOXICITY

被引：0
|
作者：
Bleeker, Gitta [1 ]
Schoot, Reineke [1 ]
Caron, Huib [1 ]
van Eck, Berthe
de Kraker, Jan [1 ]
Tytgat, Godelieve [1 ]
机构：
[1] Emma Childrens Hosp AMC, Amsterdam, Netherlands
来源：
PEDIATRIC BLOOD & CANCER | 2009年 / 53卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：736 / 736
页数：1
相关论文
共 50 条
  • [31] The impact of 131I-mIBG rescue therapy in the survival of a patient with ganglioneuroblastoma
    Parra, A. T. T.
    Moriguchi, S. M.
    Goncalves, M. C. P.
    Esteves, M. A. M. F. F.
    Santos, M. J.
    Gracioli, L. M.
    Boldrini, E.
    Rocha, E. T.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 24 : S42 - S42
  • [32] Intraarterial 131I-MIBG therapy of neuroendocrine tumours with liver metastases
    Popp, M.
    Strumpf, A.
    Zoephel, K.
    Stroszczynski, C.
    Kotzerke, J.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2010, 49 (01): : N2 - N3
  • [33] Evaluation of the efficacy of 131I-MIBG therapy for metastatic neuroendocrine tumours
    Lapinska, G. E.
    Niewiadomska, J.
    Benke, M.
    Czetwertynska, M.
    Falkowski, S.
    Kozlowicz-Gudzinska, I.
    Sackiewicz-Slaby, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S222 - S222
  • [34] Dosimetry in 131I-MIBG therapy: moving toward personalized medicine
    Chiesa, C.
    Castellani, R.
    Mira, M.
    Lorenzoni, A.
    Flux, G. D.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 57 (02): : 161 - 170
  • [35] Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma
    George, Sally L.
    Falzone, Nadia
    Chittenden, Sarah
    Kirk, Stephanie J.
    Lancaster, Donna
    Vaidya, Sucheta J.
    Mandeville, Henry
    Saran, Frank
    Pearson, Andrew D. J.
    Du, Yong
    Meller, Simon T.
    Denis-Bacelar, Ana M.
    Flux, Glenn D.
    NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (05) : 466 - 472
  • [36] Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
    Jose Genolla
    Trinidad Rodriguez
    Pablo Minguez
    Ricardo Lopez-Almaraz
    Veronica Llorens
    Aizpea Echebarria
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1567 - 1575
  • [37] 131I-MIBG scintigraphy in the diagnosis of pheochromocytoma: Retrospective study of 50 cases
    Ghomari, C. F.
    Tahraoui, Z.
    Merad, S.
    Medjahedi, A.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 144 - 144
  • [38] Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
    Genolla, Jose
    Rodriguez, Trinidad
    Minguez, Pablo
    Lopez-Almaraz, Ricardo
    Llorens, Veronica
    Echebarria, Aizpea
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (07) : 1567 - 1575
  • [39] 131I-Metaiodobenzylguanidine (131I-MIBG) double infusion with autologous stem cell transplant for neuroblastoma:: A New Approaches to Neuroblastoma Therapy (NANT) study.
    Matthay, K. K.
    Quach, A.
    Huberty, J.
    Franc, B.
    Groshen, S.
    Shusterman, S.
    Veatch, J.
    Brophy, P.
    Yanik, G.
    Maris, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 504S - 504S
  • [40] Use of 131I-MIBG Therapy in MIBG-Positive Metastatic Medullary Thyroid Carcinoma
    Maiza, Jean-Christophe
    Grunenwald, Solange
    Otal, Philippe
    Vezzosi, Delphine
    Bennet, Antoine
    Caron, Philippe
    THYROID, 2012, 22 (06) : 654 - 655
12345